Globus Medical Toekomstige groei
Future criteriumcontroles 3/6
Globus Medical zal naar verwachting groeien in winst en omzet met respectievelijk 48.3% en 6.3% per jaar. De winst per aandeel zal naar verwachting groeien met 47.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 10.8% zijn.
Belangrijke informatie
48.3%
Groei van de winst
47.9%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 17.7% |
| Inkomstengroei | 6.3% |
| Toekomstig rendement op eigen vermogen | 10.8% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 06 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Globus Medical (NYSE:GMED) Has A Rock Solid Balance Sheet
Nov 04
Globus Medical, Inc.'s (NYSE:GMED) Shareholders Might Be Looking For Exit
Oct 14Globus Medical: A Post Acquisition Analysis
Aug 26Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors
Jun 28An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Apr 08Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly
Mar 20Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock
Feb 27Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?
Feb 09Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings
Jan 17Globus Medical: Merger Overhang Lingering
Nov 27Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?
Nov 14Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?
Oct 27Globus Medical: Almost Having My Back
Sep 13Globus Medical: Slightly Too Pricey Right Now
Aug 07Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Jul 18Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Jul 11Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching
Jun 18Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Apr 09What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?
Mar 22Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?
Feb 24Globus Medical Q4 2022 Earnings Preview
Feb 20Globus Medical: An Impressive Long-Term Revenue Growth Play
Jan 08Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
Dec 22Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends
Dec 01Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line
Nov 08A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)
Oct 15Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact
Sep 02Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Sep 02Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?
Aug 11Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective
Jun 05Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital
May 24Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 2,844 | 478 | N/A | N/A | 10 |
| 12/31/2025 | 2,663 | 411 | 593 | N/A | 14 |
| 12/31/2024 | 2,498 | 137 | 458 | N/A | 12 |
| 9/30/2024 | 2,479 | 92 | 294 | 415 | N/A |
| 6/30/2024 | 2,237 | 41 | 161 | 262 | N/A |
| 3/31/2024 | 1,898 | 67 | 152 | 243 | N/A |
| 12/31/2023 | 1,568 | 123 | 165 | 243 | N/A |
| 9/30/2023 | 1,226 | 158 | 129 | 203 | N/A |
| 6/30/2023 | 1,097 | 204 | 121 | 185 | N/A |
| 3/31/2023 | 1,069 | 201 | 117 | 187 | N/A |
| 12/31/2022 | 1,023 | 190 | 104 | 178 | N/A |
| 9/30/2022 | 998 | 155 | 118 | 191 | N/A |
| 6/30/2022 | 974 | 155 | 157 | 235 | N/A |
| 3/31/2022 | 961 | 142 | 194 | 257 | N/A |
| 12/31/2021 | 958 | 149 | 219 | 276 | N/A |
| 9/30/2021 | 942 | 187 | 226 | 280 | N/A |
| 6/30/2021 | 928 | 184 | 203 | 256 | N/A |
| 3/31/2021 | 826 | 122 | 165 | 220 | N/A |
| 12/31/2020 | 789 | 102 | 135 | 199 | N/A |
| 9/30/2020 | 767 | 95 | 108 | 173 | N/A |
| 6/30/2020 | 747 | 89 | 115 | 176 | N/A |
| 3/31/2020 | 793 | 148 | 110 | 175 | N/A |
| 12/31/2019 | 785 | 155 | 101 | 172 | N/A |
| 9/30/2019 | 770 | 146 | 90 | 162 | N/A |
| 6/30/2019 | 743 | 143 | 82 | 158 | N/A |
| 3/31/2019 | 722 | 150 | 93 | 169 | N/A |
| 12/31/2018 | 713 | 156 | 122 | 182 | N/A |
| 9/30/2018 | 693 | 144 | 126 | 182 | N/A |
| 6/30/2018 | 676 | 134 | N/A | 165 | N/A |
| 3/31/2018 | 655 | 118 | N/A | 158 | N/A |
| 12/31/2017 | 636 | 107 | N/A | 159 | N/A |
| 9/30/2017 | 612 | 107 | N/A | 166 | N/A |
| 6/30/2017 | 595 | 108 | N/A | 174 | N/A |
| 3/31/2017 | 581 | 105 | N/A | 171 | N/A |
| 12/31/2016 | 564 | 104 | N/A | 148 | N/A |
| 9/30/2016 | 553 | 118 | N/A | 166 | N/A |
| 6/30/2016 | 554 | 118 | N/A | 153 | N/A |
| 3/31/2016 | 548 | 116 | N/A | 143 | N/A |
| 12/31/2015 | 537 | 113 | N/A | 124 | N/A |
| 9/30/2015 | 518 | 103 | N/A | 80 | N/A |
| 6/30/2015 | 499 | 99 | N/A | 85 | N/A |
| 3/31/2015 | 481 | 96 | N/A | 85 | N/A |
| 12/31/2014 | 467 | 92 | N/A | 79 | N/A |
| 9/30/2014 | 454 | 86 | N/A | 110 | N/A |
| 6/30/2014 | 443 | 83 | N/A | 108 | N/A |
| 3/31/2014 | 436 | 70 | N/A | 104 | N/A |
| 12/31/2013 | 427 | 69 | N/A | 93 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei GMED ( 48.3% per jaar) ligt boven de spaarquote ( 2.6% ).
Winst versus markt: De winst van GMED ( 48.3% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).
Hoge groeiwinsten: De winst van GMED zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van GMED ( 6.3% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van GMED ( 6.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen GMED zal naar verwachting over 3 jaar laag zijn ( 10.8 %).